» Articles » PMID: 10602719

Efficacies of Topical Formulations of Foscarnet and Acyclovir and of 5-percent Acyclovir Ointment (Zovirax) in a Murine Model of Cutaneous Herpes Simplex Virus Type 1 Infection

Overview
Specialty Pharmacology
Date 1999 Dec 22
PMID 10602719
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The topical efficacies of foscarnet and acyclovir incorporated into a polyoxypropylene-polyoxyethylene polymer were evaluated and compared to that of 5% acyclovir ointment (Zovirax) by use of a murine model of cutaneous herpes simplex virus type 1 infection. All three treatments given three times daily for 4 days and initiated 24 h after infection prevented the development of the zosteriform rash in mice. The acyclovir formulation and the acyclovir ointment reduced the virus titers below detectable levels in skin samples from the majority of mice, whereas the foscarnet formulation has less of an antiviral effect. Reducing the number of treatments to a single application given 24 h postinfection resulted in a significantly higher efficacy of the formulation of acyclovir than of the acyclovir ointment. Acyclovir incorporated within the polymer was also significantly more effective than the acyclovir ointment when treatment was initiated on day 5 postinfection. The higher efficacy of the acyclovir formulation than of the acyclovir ointment is attributed to the semiviscous character of the polymer, which allows better penetration of the drug into the skin.

Citing Articles

Polymeric Nanoparticles as Tunable Nanocarriers for Targeted Delivery of Drugs to Skin Tissues for Treatment of Topical Skin Diseases.

Madawi E, Al Jayoush A, Rawas-Qalaji M, Thu H, Khan S, Sohail M Pharmaceutics. 2023; 15(2).

PMID: 36839979 PMC: 9964857. DOI: 10.3390/pharmaceutics15020657.


Ginkgolic Acid Inhibits Herpes Simplex Virus Type 1 Skin Infection and Prevents Zosteriform Spread in Mice.

Bhutta M, Shechter O, Gallo E, Martin S, Jones E, Doncel G Viruses. 2021; 13(1).

PMID: 33435520 PMC: 7826900. DOI: 10.3390/v13010086.


Fabrication of acyclovir-loaded flexible membrane vesicles (FMVs): evidence of preclinical efficacy of antiviral activity in murine model of cutaneous HSV-1 infection.

Sharma G, Thakur K, Setia A, Amarji B, Singh M, Raza K Drug Deliv Transl Res. 2017; 7(5):683-694.

PMID: 28801835 DOI: 10.1007/s13346-017-0417-0.


Development of novel microemulsion-based topical formulations of acyclovir for the treatment of cutaneous herpetic infections.

Shishu , Rajan S, Kamalpreet AAPS PharmSciTech. 2009; 10(2):559-65.

PMID: 19504745 PMC: 2690805. DOI: 10.1208/s12249-009-9242-1.


Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery.

Abla N, Naik A, Guy R, Kalia Y Pharm Res. 2006; 23(8):1842-9.

PMID: 16850271 DOI: 10.1007/s11095-006-9017-2.


References
1.
Descamps J, De Clercq E, Barr P, Jones A, Walker R, Torrence P . Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice. Antimicrob Agents Chemother. 1979; 16(5):680-2. PMC: 352929. DOI: 10.1128/AAC.16.5.680. View

2.
Spruance S, Rea T, Thoming C, Tucker R, Saltzman R, Boon R . Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA. 1997; 277(17):1374-9. View

3.
Corey L, Nahmias A, Guinan M, Benedetti J, Critchlow C, Holmes K . A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med. 1982; 306(22):1313-9. DOI: 10.1056/NEJM198206033062201. View

4.
Spruance S, Crumpacker C . Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis. Antiviral effect without clinical benefit. Am J Med. 1982; 73(1A):315-9. DOI: 10.1016/0002-9343(82)90115-2. View

5.
Reichman R, Badger G, Guinan M, Nahmias A, Keeney R, Davis L . Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J Infect Dis. 1983; 147(2):336-40. DOI: 10.1093/infdis/147.2.336. View